Letter to Eligible Shareholders
Released
Released
Announcement PDF
L30, Collins Place, 35 Collins Street, Melbourne, VIC 3000, Australia
E: info@PercheronTx.com ■ T: +61 3 9827 8999
www.PercheronTx.com
24 March 2026
Dear Shareholder
Notice to Eligible Shareholders of Non-renounceable Entitlement Offer
We write to you as the registered holder of fully paid ordinary shares (Shares) in Percheron Therapeutics
Limited (ACN 095 060 745) (ASX:PER) (Company) as at 7.00pm (AEDT) on 20 March 2026 (Record Date).
As announced on 16 March 2026, the Company is undertaking a non-renounceable pro-rata offer of new
fully paid ordinary shares (New Shares) under which Eligible Shareholders (defined below) will be offered
two (2) New Shares for every five (5) existing Shares held on the Record Date at an issue price of $0.005 per
New Share (Entitlement Offer). Participants in the Entitlement Offer will also be issued one (1) free-
attaching option for every two (2) New Shares subscribed for and issued (New Options). The New Options
will expire two years from the date of issue and have an exercise price of $0.01.
Any New Shares and New Options not validly subscribed for pursuant to the Entitlement Offer will be offered
for subscription under a separate offer (Shortfall Offer). Eligible Shareholders who have applied for their
entitlement in full may apply for additional New Shares and New Options (Shortfall Securities) under the
Shortfall Offer, subject at all times to the Directors’ discretion to scale back applications under the Shortfall
Offer and otherwise in accordance with the allocation policy set out in the Prospectus lodged with ASIC on
16 March 2026. The Shortfall Securities will be offered on the same terms as the New Shares and New
Options to be issued under the Entitlement Offer.
All of the New Shares to be issued pursuant to the Entitlement Offer, and on exercise of the New Options,
will rank equally with the existing Shares on issue in the Company from the date of allotment. Further details
regarding the rights and liabilities attaching to the New Shares and New Options is contained in the
Prospectus.
Capitalised terms used, but not defined, in this letter have the meaning ascribed to them in the Prospectus.
Shareholders who are eligible to participate in the Entitlement Offer (Eligible Shareholders) are
shareholders who as at the Record Date:
• are registered as a holder of Shares; and
• have a registered address in Australia or, subject to the offer restrictions outlined in the Prospectus, New
Zealand, Singapore, Hong Kong or the United Kingdom.
Please note that Shares will be quoted on an ‘ex’ basis from 19 March 2026 and, therefore, any Shares
acquired on or after this date will not be entitled to participate in the Entitlement Offer and the Shortfall
Offer.
The Entitlement Offer is non-renounceable, meaning that Eligible Shareholders will not be able to transfer
their entitlements pursuant to the Entitlement Offer.
The Entitlement Offer is joint lead managed by Blue Ocean Equities and Cygnet Capital. The Entitlement
Offer is not underwritten.
It is important that you read the Prospectus carefully and in its entirety. You should seek advice from your
suitably qualified professional adviser if you have any queries.
Further details on the Entitlement Offer can be found in the Prospectus.
How to access the Entitlement Offer and Prospectus
1. ONLINE – Eligible Shareholders can access their personalised Entitlement and Acceptance Form
online at https://www.investorserve.com.au/.
2. PAPER – Request a paper copy of the Prospectus and the personalised application form by
contacting the Company Secretary by telephone on 61 411 828 748 or by email at
deborah.ambrosini@percherontx.com.
This notice is to inform you of the Entitlement Offer. You are not required to do anything in respect to this
letter.
Indicative Timetable
Event Date (2026)*
Lodgement of this Prospectus with ASIC Monday, 16 March
Lodgement of Appendix 3B and Prospectus with ASX
Announcement of Offers
Monday, 16 March
Ex Date Thursday, 19 March
Record Date for the Entitlement Offer (Record Date) 7.00pm (AEDT) on
Friday, 20 March
Prospectus and Entitlement and Acceptance Form dispatched to Eligible
Shareholders and the Company announces that this has occurred
Opening Date of Offers
Tuesday, 24 March
Last day to extend the Closing Date of the Offers Wednesday, 1 April
Closing Date of Offers 5:00pm (AEST) on
Wednesday, 8 April
Unless otherwise determined by ASX, New Shares quoted on a deferred
settlement basis from market open
Thursday, 9 April
Announcement of the results of the Offers
Allotment of New Shares and New Options and lodgement of Appendix
2A and Appendix 3G
Wednesday, 15 April
Anticipated date of quotation of New Shares issued under the Offers Thursday, 16 April
*All dates (other than those which have occurred as at the date of this letter) are indicative only. The
Company retains the discretion, subject to the ASX Listing Rules and the Corporations Act, to alter key dates
at its discretion (generally or in particular cases), without prior notice. The Company also reserves the right
not to proceed with the Offers at any time before the issue of Securities.
Further information
For further information on the Entitlement Offer you may contact the Company Secretary Ms Deborah
Ambrosini on 61 411 828 748 or deborah.ambrosini@percherontx.com. For all general shareholder
enquiries, please contact the Company's Share Registry Boardroom Pty Limited on 1300 737 760 (within
Australia) or +61 2 9290 9600 (outside Australia).
Yours faithfully
Dr Charmaine Gittleson
Non-Executive Chair
Percheron Therapeutics Limited
Share your feedback
Discover